Evaluation of an Indirect Immunofluorescence Assay for Strongyloidiasis as a Tool for Diagnosis and Follow-Up
- 1 February 2007
- journal article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (2) , 129-133
- https://doi.org/10.1128/cvi.00278-06
Abstract
The diagnostic accuracy of an indirect immunofluorescence antibody test (IFAT) for Strongyloides stercoralis at different serum antibody titers was evaluated. To assess diagnostic sensitivity, sera from 156 patients with known strongyloidiasis were collected. Negative control sera were obtained from a composite group of 427 subjects (blood donors and hospitalized patients). With an area under the receiver-operating characteristic plot of 0.98, the IFAT showed a high level of diagnostic accuracy for strongyloidiasis. An antibody titer of ≥1:20, with 97% sensitivity and 98% specificity, was identified as the diagnostic threshold with the best overall performance. Cross-reactions were evaluated with 41 additional samples from patients with other known helminth infections, and the IFAT detected low-titer positivity in only one subject with filariasis. A positive IFAT result at an antibody dilution of ≥1:80 was virtually 100% specific, with 71% sensitivity. To test the usefulness of the IFAT as a monitoring tool, the changes in specific-antibody titers after treatment in a group of 155 patients were evaluated. Seroreversion or a decrease in antibody titer of twofold or more was observed in 60% of the patients. Response to treatment was directly correlated to the initial antibody titer, and a baseline titer of ≥1:80 was identified as the best predictor of response. In conclusion, a positive IFAT result at an antibody dilution of ≥1:20 is the optimal cutoff for screening. A titer of ≥1:80, with virtually no false-positive result, is a reliable cutoff for a serological assessment of treatment efficacy and for inclusion in clinical trials.Keywords
This publication has 59 references indexed in Scilit:
- Unsuspected strongyloidiasis in hospitalised elderly patients with and without eosinophiliaClinical Microbiology & Infection, 2006
- Strongyloidiasis: A review of the evidence for Australian practitionersAustralian Journal of Rural Health, 2005
- Disseminated strongyloidiasis in a patient with acquired immunodeficiency syndromeEuropean Journal of Internal Medicine, 2004
- Strongyloides stercoralisin the Immunocompromised PopulationClinical Microbiology Reviews, 2004
- Parasite-specific serum IgG following successful treatment of endemic strongyloidiasis using ivermectinTransactions of the Royal Society of Tropical Medicine and Hygiene, 1996
- Value of the agar plate method for the diagnosis of intestinal strongyloidiasisDiagnostic Microbiology and Infectious Disease, 1995
- Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: results of an open study of 60 casesTransactions of the Royal Society of Tropical Medicine and Hygiene, 1994
- Diagnostic Medical ParasitologyJournal of Parasitology, 1994
- Application of enzyme immunoassay for postchemotherapy evaluation of human strongyloidiasisDiagnostic Microbiology and Infectious Disease, 1994
- Disseminated strongyloidiasis: An unheralded risk of corticosteroid therapyJournal of Allergy and Clinical Immunology, 1990